Alnylam Pharmaceuticals
ALNY
#436
Rank
ยฃ39.94 B
Marketcap
ยฃ302.37
Share price
0.32%
Change (1 day)
52.19%
Change (1 year)
Alnylam Pharmaceuticals Inc. is a biopharmaceutical company focused on the R&D and commercialization of RNA interference (RNAi) therapeutics for genetically defined diseases.

Alnylam Pharmaceuticals (ALNY) - Cash on Hand

Cash on Hand as of September 2025 : ยฃ2.03 Billion

According to Alnylam Pharmaceuticals 's latest financial reports the company has ยฃ2.03 Billion in cash and cash equivalents.
A companyโ€™s cash on hand also refered as cash/cash equivalents (CCE) and Short-term investments, is the amount of accessible money a business has.

Alnylam Pharmaceuticals - Cash on Hand chart (from 2003 to 2025)

Cash on Hand by year

Year Cash on Hand Change
2024-12-31ยฃ2.14 B12.14%
2023-12-31ยฃ1.91 B5.66%
2022-12-31ยฃ1.81 B0.44%
2021-12-31ยฃ1.80 B31.21%
2020-12-31ยฃ1.37 B17.38%
2019-12-31ยฃ1.17 B37.16%
2018-12-31ยฃ0.85 B-31.72%
2017-12-31ยฃ1.25 B146.25%
2016-12-31ยฃ0.50 B-30.33%
2015-12-31ยฃ0.72 B62.94%
2014-12-31ยฃ0.44 B200.21%
2013-12-31ยฃ0.14 B96.17%
2012-12-31ยฃ75.98 M-19.33%
2011-12-31ยฃ94.19 M-37.63%
2010-12-31ยฃ0.15 B-13.16%
2009-12-31ยฃ0.17 B-40.78%
2008-12-31ยฃ0.29 B49.61%
2007-12-31ยฃ0.19 B76.97%
2006-12-31ยฃ0.11 B139.08%
2005-12-31ยฃ46.39 M93.42%
2004-12-31ยฃ23.98 M84.99%
2003-12-31ยฃ12.96 M34.32%
2002-12-31ยฃ9.65 M

Cash on Hand for similar companies or competitors

Company Cash on Hand differencediff. Country
Arrowhead Pharmaceuticals
ARWR
ยฃ0.67 B-66.95%๐Ÿ‡บ๐Ÿ‡ธ USA
Regeneron Pharmaceuticals
REGN
ยฃ6.29 B 209.90%๐Ÿ‡บ๐Ÿ‡ธ USA
Sarepta Therapeutics
SRPT
ยฃ0.63 B-68.77%๐Ÿ‡บ๐Ÿ‡ธ USA
OPKO Health
OPK
ยฃ0.30 B-84.76%๐Ÿ‡บ๐Ÿ‡ธ USA
Regulus Therapeutics
RGLS
ยฃ48.71 M-97.60%๐Ÿ‡บ๐Ÿ‡ธ USA
Novartis
NVS
ยฃ7.26 B 257.96%๐Ÿ‡จ๐Ÿ‡ญ Switzerland
Sanofi
SNY
ยฃ7.78 B 283.61%๐Ÿ‡ซ๐Ÿ‡ท France
Teva Pharmaceutical Industries
TEVA
ยฃ1.64 B-19.14%๐Ÿ‡ฎ๐Ÿ‡ฑ Israel